Overview

Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma

Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of LBH489B in adult patients with refractory Cutaneous T-Cell Lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Bexarotene
Panobinostat